Comparative analysis of global practices in the management of colchicine-resistant familial Mediterranean fever: a CliPS network analysis
Journal
RMD open
Date Issued
2025-09-26
Author(s)
Haslak, Fatih
Oner, Nimet
Elhani, Inès
Hinze, Tanja
Mamutova, Anna
Bourguiba, Rim
Kasap Cuceoglu, Muserref
Pateras, Konstantinos
Aviel, Yonatan Butbul
Delplanque, Marion
Caorsi, Roberta
Šestan, Mario
Bénard, Stéphanie Ducharme
Brunner, Jürgen
El Moussaoui, Majdouline
Constantin, Tamas
Arenas, Sonia Carriquí
Khellaf, Ghalia
Guliyeva, Vafa
Assalia, Naiera
Backes, Stefan
Sozeri, Betul
Hofer, Michaël
Ayaz, Nuray
Lachmann, Helen
Wittkowski, Helmut
Hentgen, Véronique
DOI
10.1136/rmdopen-2025-006097
Abstract
Although colchicine is the mainstay of familial Mediterranean fever (FMF) treatment, 5-10% of patients are considered to have colchicine resistance (CR). However, there is no globally agreed CR definition or indications for biological disease-modifying anti-rheumatic drugs (bDMARDs).